康躍科技(300391.SZ):擬取得國潤生物36%的股權
格隆匯7月7日丨康躍科技(300391.SZ)公佈,公司於2021年7月7日與淄博景星澤企業管理諮詢合夥企業(有限合夥)(“景星澤”)、淄博凱澤鑫企業管理諮詢合夥企業(有限合夥)(“凱澤鑫”)、國潤生物科技(深圳)有限公司(“國潤生物”、“標的公司”)簽署《合作意向協議》,公司擬通過包括但不限於股權收購、增資擴股等方式取得國潤生物36%的股權。
國潤生物是一家主要圍繞生物技術推廣、生物製品的技術可開發、生物科技產品的技術開發、藥物的技術開發以及二類醫療器械及相關設備的研發、銷售、技術服務、技術諮詢以及新型藥物研發等生物醫藥領域技術研發型企業。景星澤與凱澤鑫為國潤生物的股東,合計持股國潤生物100%的股權。
國潤生物是集精準原料開發、應用配方創新、出品標準化體系管理為一體的孵化生物醫療上游產品的高新技術企業。
此次意向交易是公司聚焦大健康戰略的新舉措,是公司向大健康產業內更高附加值領域延伸的戰略性佈局。公司基於原有中醫藥產業形成的基礎性草本原料加工、GMP生產、下游渠道支持等的基礎能力,結合標的公司在原料開發、配方創新、產品應用等的核心優勢,拓展公司大健康業務領域。
此次意向交易是適應市場和業務發展的需要,有利於推動公司業務升級,有利於公司在現有業務的基礎上開闢新業務領域,形成新增盈利增長點,有利於提升公司可持續發展能力、競爭力和盈利能力,有利於上市公司和投資者利益的最大化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.